.

 1998 5

- (5)




5-

()-1998

,
,


,

!

1992
-
.
4

:




.... ()




.

Recommendations of the 1st International Consultation on . In: Jardin A et al., eds. Erectile
Dysfunction. Plymouth, UK: Health Publication, Ltd; 2000:711-726.


NO

-



.
.


.
.


.
,
.

 40
50% .

150 .
21 10 1

.
40
5%, 70 15%
.

35%



. :
1.
2.

68%

80%

75%

75%

44%

Mulcahy JJ. Male Sexual function 2001, 94-97,214. Rosen RC. Sexual dysfunction as on obstacle to compliance with antihypertensive therapy,
1997,47-51. Prisant LM, Bottini PB, Solursh. Sexual disfunction with antihypertensive drug. 1994, 154, 730-736. Kloner. ED in the cardiac
patient/1999,53,445-451.
Jacksons. A systematic approach to ED in the cardiovascular patient.
11

 -

- M.K. Walczak et al

..
1. Impotence may be12early warning disease. Atlanta. American Heart Association , Nov 10, 1999.

, ,

,

.
*



(EAU,2001 . AUA 1996)
1- :

( 5
(5)
)
-

2-

( 1,
, VIP, )

( 1)
3- :
( )

-:

: 1992


IIEF 1115

IIEF 16-20

Goldstein I, et al. NEJM 1998;338:1397-1404.

IIEF 25-21

IIEF 1115

Mulhall JP, et al.. J Sex Med. 2007


1998 3 FDA -

()
.
1998 10 13
,
-
.


/188 / ,

BEDELL S . E . ET AL ., 2002

(%)
81

52

73
9
23

25
33
10
6
3

-
-

60%

57%

68%
64%

56%

 2 1 -5
?

 10 1
*

10 8
.*

*MMAS, 1994

120130

150180

3-5 ,
5-15

, 1999 .
DeBusk et al. Am J Cardiol.2000; 86: 175- 181.

AM J CARDIOLOGY , 2000; 86: 175-181

max .

14 30 .

7

.
24

.


(/)

(100 ) -

24
.

500

400

100 - .

300
200
100
0

10

15

()
: Data on file. Pfizer Inc., NY, NY.

20

25

 -5

( )



(RX-RA 69)

20- 80-



.
%

100

80

60

40

20

McMurray JG, Feldman RA, Auerbach SM, deRiesthal H, Wilson N. Long-term effectiveness and tolerability of Viagra (sildenafil citrate) in men with
erectile dysfunction. Poster presented at: International Society for Sexual and Impotence Research; September 22-26, 2002; Montreal, Canada.

 5-

 5-


Change compared with the original
condition ( %)

30
25

26.5

20

20.4

-5

17.3

15

10
9.8
5
4.7
0

4.7

,

ST 1
*P < 0.05.

Data on file, Pfizer Inc, New York, NY.

.


1
5

4,90
0,84

0,80

3
0.5

0.53
2

100 -

100 -

3,90

2,30

1
0

-5

-5

-5

-5

-5
- , -5
, 1, 2
1. Mittleman M., Maclure M., Glasser D. Evaluation of acute risk for myocardial infarction in men treated with
sildenafil citrate. Am J Cardiol 2005; 96: 443446.
2. Zusman R., Morales A., Glasser D. Osterloh I. Overall cardiovascular profile of sildenafil citrate. Am J Cardiol
1999; 83: 35C44C.

- ,
:

Mancia, et al. J. Hypertension 2009; 27; 2121-2158

-5 - -11

15

780

-11-
-




?
,

 ,



,
,
300

:
,

 -5

,
,
.

,

48